Tarsier Pharma

Company Overview

Snapshot

Founded in January 2016 by Daphne Haim-Langford, Tarsier Pharma operates with 11–50 employees. The company has raised $5.65 million across three funding rounds. In January 2025, Tarsier Pharma appointed.

Business overview

Tarsier Pharma is a late-clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutic approaches for autoimmune inflammatory ocular diseases. The company's core technology is the TRS Platform, a bio-inspired immunomodulator designed to treat blinding inflammatory ocular conditions. This platform is being developed as both eye drops and intravitreal injections, aiming to control a range of autoimmune and inflammatory ocular diseases as effectively as steroids but without their negative side effects. Tarsier Pharma operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and medical biotechnology markets with a focus on drug discovery and development.

Strategic signal

In May 2026, Tarsier Pharma announced its progression towards an IPO in New York, signaling strong market confidence and a strategic move to access broader capital markets. This development indicates the company's readiness to scale its operations and accelerate the commercialization of its late-clinical-stage assets, particularly its lead candidate TRS01, for autoimmune inflammatory ocular diseases.

Company Intelligence Q&A

What is the latest strategic development for Tarsier Pharma?

In May 2026, Tarsier Pharma announced its advancement towards an Initial Public Offering (IPO) in New York, indicating a significant step in its growth and market expansion strategy.

Who was recently appointed to a key leadership position at Tarsier Pharma?

In January 2025, Tarsier Pharma appointed Ashley Kline as Chief Commercial Officer. This appointment aims to expand the company's US presence and lead commercial planning for its pipeline, including the lead asset, TRS01.

What new product development did Tarsier Pharma announce?

In August 2022, Tarsier Pharma announced the development of TRS02, a slow-release formulation of TRS for intravitreal injection, designed to treat retinal diseases with underlying inflammatory pathology. The company has achieved significant pre-clinical milestones for TRS02.

Which investors participated in Tarsier Pharma's funding rounds?

Tarsier Pharma has received funding from investors including a wholly owned subsidiary of Sun Pharmaceutical Industries Limited.

What significant regulatory milestone did Tarsier Pharma achieve for its TRS program?

In November 2019, Tarsius Pharma received Orphan Drug Designation from the European Medicines Agency (EMA) for its TRS program, intended for the treatment of non-infectious uveitis. This designation acknowledged the significant benefit of TRS for uveitis patients with glaucoma.